Does an oral analgesic protocol improve pain control for patients with cancer? An intergroup study coordinated by the Eastern Cooperative Oncology Group
Cleeland, C. S.
Portenoy, R. K.
Mendoza, T. R.
Atkins, J. N.
Johnson, P. A.
MetadataShow full item record
Background: Cancer pain is highly prevalent and commonly undertreated. This study was designed to determine whether dissemination of a clinical protocol for pain management would improve outcomes in community oncology practices. Patients and methods: A pain management protocol was developed based on accepted guidelines. After baseline assessment, oncology practices were randomly assigned to ‘analgesic protocol’ (AP) sites, where oncologists implemented the guidelines in a group of lung or prostate cancer patients, or to ‘physician discretion’ (PD) sites, where customary treatment was continued. Patients treated on protocol and a comparison group of patients with pain due to breast cancer or myeloma were monitored for change in pain using the Brief Pain Inventory, and for change in other symptoms or mood. Results: The protocol terminated early because of poor accrual. We compared groups using proportions of patients who had no or mild pain at follow-up. Although measures of protocol adherence did not suggest the occurrence of major practice change, the proportion of lung or prostate cancer patients with no or mild pain increased significantly from baseline for those treated at AP sites compared with those treated at PD sites. There was no significant difference between the breast and myeloma patients treated at AP sites versus those treated at PD sites. Conclusion: A protocol for cancer pain management can improve pain control. Diffusion of these benefits to other patients was not confirmed. Given the small sample size, these findings require confirmation in a larger trial.
Is part ofAnnals of Oncology, 2005, vol. 16, núm. 6, p. 972-980
European research projects
Showing items related by title, author, creator and subject.
Multicenter Phase 2 Trial of Rituximab for Waldenström Macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98) Gertz, Morie A.; Rué i Monné, Montserrat; Blood, Emily; Kaminer, Lynne S.; Vesole, David H.; Greipp, Philip R. (Taylor & Francis, 2004)Waldenström macroglobulinemia (WM) is a low-grade lymphoplasmacytic lymphoma that strongly expresses CD20 on the cell surface. This study was undertaken to determine the response rate of patients with untreated or ...
Virgin olive oil enriched with its own phenolic compounds or complemented with thyme improves endothelial function: The potential role of plasmatic fat-soluble vitamins. A double blind, randomized, controlled, cross-over clinical trial Valls, Rosa M.; Farràs, Marta; Pedret, Anna; Fernández Castillejo, Sara; Catalán Santos, Úrsula; Romeu, Marta; Giralt, Montserrat; Sáez, Guillermo T.; Fitó, Montserrat; De la Torre, Rafael; Covas Planells, María Isabel; Motilva Casado, Mª José; Solà, Rosa; Rubió Piqué, Laura (Elsevier, 2017)The aim of the present study was to assess whether different functional virgin olive oils (FVOOs) with varying phenolic compounds (PC) could protect the plasmatic fat-soluble vitamins, which in turn could improve the ...
The effect of information about the benefits and harms of mammography on women’s decision-making: study protocol for a randomized controlled trial Misericòrdia, Carles; Martínez Alonso, Montserrat; Pons Rodríguez, Anna; Pérez Lacasta, María José; Perestelo Pérez, Lilisbeth; Sala, Maria; Vidal, Carmen; Garcia, Montse; Toledo Chávarri, Ana; Codern, Núria; Feijoo Cid, Maria; Romero, Anabel; Pla, Roger; Soler González, Jorge; Castells, Xavier; Rué i Monné, Montserrat (BioMed Central, 2017)The decision to participate or not in breast cancer screening is complex due to the trade-off between the expected benefit of breast cancer mortality reduction and the major harm of overdiagnosis. It seems ethically necessary ...